Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries

2018 ◽  
Vol 59 (9) ◽  
pp. 2113-2120
Author(s):  
Graham P. Collins ◽  
Antonio Rueda ◽  
Gilles Salles ◽  
Bastian von Tresckow ◽  
Francesco Zaja
2019 ◽  
Vol 37 (4) ◽  
pp. 490-492
Author(s):  
Ioanna Sakellari ◽  
Eleni Gavriilaki ◽  
Michail Iskas ◽  
Zoi Bousiou ◽  
Aristotelis Chatziioannidis ◽  
...  

2016 ◽  
Vol 19 (7) ◽  
pp. A752-A753
Author(s):  
D von Bredow ◽  
N Kolb ◽  
M Bernhardt ◽  
N Schmidt

2020 ◽  
Vol 16 (15) ◽  
pp. 1001-1012
Author(s):  
Burkhard Otremba ◽  
Jens Borchardt ◽  
Andra Kuske ◽  
Maike Hollnagel-Schmitz ◽  
Florian O Losch

Aim: Present real-world data for rituximab (biosimilar and reference)-containing regimens in extrapolated indications in non-Hodgkin lymphoma (NHL)/chronic lymphocytic leukemia (CLL). Patients & methods: Data collected from office-based oncologic practices in Germany (July 2017–June 2019). Results: Of 1741 patients, 1241 had NHL; 500 had CLL. Of 7595 therapy cycles, 28.3% used reference rituximab; 55.2% used rituximab biosimilars; 2.0% used subcutaneous rituximab; 14.5% used rituximab, not otherwise specified. Rituximab biosimilars were used across all indications; 57.3% of cycles were administered in extrapolated indications. Over 24 months, the proportion of rituximab prescriptions that were for biosimilars increased from 12.0 to 83.0%. Conclusion: Our real-world data in NHL and CLL depicts increasing use of rituximab biosimilars across multiple treatment protocols, including extrapolated indications.


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Kerstin Becker ◽  
Klaas Heinemann ◽  
Bruno Imthurn ◽  
Lena Marions ◽  
Sabine Moehner ◽  
...  

AbstractEndometriosis is a chronic disease that requires a suitable, lifelong treatment. To our knowledge, the Visanne Post-approval Observational Study (VIPOS) is to date the largest real-world, non-interventional study investigating hormonal management of endometriosis. We describe women’s experiences of endometriosis in the real world by considering their symptoms and the diagnostic process in their healthcare setting. Overall, 27,840 women were enrolled from six European countries via networks of gynecologists or specialized centers. Of these, 87.8% of women were diagnosed based on clinical symptoms; the greatest and lowest proportions of women were in Russia (94.1%) and Germany (61.9%), respectively. Most women (82.8%) experienced at least one of the triad of endometriosis-associated pain symptoms: pelvic pain, pain after/during sexual intercourse, and painful menstrual periods. The most frequently reported endometriosis-associated symptoms were painful periods (61.8%), heavy/irregular bleeding (50.8%), and pelvic pain (37.2%). Women reported that endometriosis impacted their mood; 55.6% reported feeling “down”, depressed, or hopeless, and 53.2% reported feeling like a failure or having let down family/friends. VIPOS broadens our understanding of endometriosis based on real-world data by exploring the heterogeneity of symptoms women with endometriosis experience and the differences in diagnostic approaches between European countries.Trial registration: ClinicalTrials.gov, NCT01266421; registered 24 December 2010. Registered in the European Union electronic Register of Post-Authorisation Studies as number 1613.


2019 ◽  
Vol 10 (21) ◽  
pp. 5041-5048 ◽  
Author(s):  
Zdeněk Král ◽  
Jozef Michalka ◽  
Heidi Móciková ◽  
Jana Marková ◽  
Alice Sýkorová ◽  
...  

2016 ◽  
Vol 22 ◽  
pp. 219
Author(s):  
Roberto Salvatori ◽  
Olga Gambetti ◽  
Whitney Woodmansee ◽  
David Cox ◽  
Beloo Mirakhur ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document